Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030

Benzinga · 08/03 14:22
Guggenheim analyst Brad Canino maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $1000 to $1030.